Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2024.150395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Vivian N V Bui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, 8000, Aarhus, Denmark. Electronic address: vbui1103@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, DNA Methylation, Drug Resistance, Neoplasm, ErbB Receptors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment of non-small-cell lung cancer (NSCLC) patients possessing EGFR-activating mutations with tyrosine kinase inhibitors (TKIs) can confer an initial promising response. However, TKI resistance inevitably arises. Numerous TKI resistance mechanisms are identified including EGFR secondary mutations, bypass receptor tyrosine kinase (RTK) signaling, and cellular transition e.g. epithelial-mesenchymal transition (EMT). To increase the knowledge of TKI resistance we performed an epigenetic screen to identify small non-coding (nc) genes with DNA methylation alterations in HCC827 NSCLC EGFR-mutated cells with acquired TKI resistance. We analyzed Infinium Methylation EPIC 850K Array data for DNA methylation changes present in both TKI-resistant HCC827 cells with EMT and MET-amplification. Hereby, we identified that the polymorphic maternal imprinted gene nc886 (vtRNA2-1) has a decrease in promoter DNA methylation in TKI-resistant cells. This epigenetic change was associated with an increase in the expression of nc886. The induction of EMT did not affect nc886 expression. CRISPR/Cas9-mediated distortion of the nc886 sequence increased the sensitivity of HCC827 cells towards TKI. Finally, nc886 sequence distortion hindered MET RTK activation and instead was EMT the endpoint TKI resistance mechanism. In conclusion, the expression of nc886 contributes to TKI resistance in the HCC827 NSCLC cell line by supporting cell survival and selection of the endpoint TKI resistance mechanism. We propose DNA methylation and expression changes for nc886 to constitute a novel TKI resistance contributing mechanism in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Aarhus University, 8000, Aarhus, Denmark. Electronic address: vbui1103@gmail.com.
- Department of Biomedicine, Aarhus University, 8000, Aarhus, Denmark. Electronic address: tfm@biomed.au.dk.
- Department of Clinical Biochemistry, Aarhus University Hospital, 8200, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, 8200, Aarhus, Denmark. Electronic address: boesoere@rm.dk.
- Department of Biomedicine, Aarhus University, 8000, Aarhus, Denmark. Electronic address: aln@biomed.au.dk.
Zitieren
APA
Bui, V. N. V., Daugaard, T. F., Sorensen, B. S., & Nielsen, A. L. (2024). Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150395
Vancouver
Bui VNV, Daugaard TF, Sorensen BS, Nielsen AL. Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150395
BibTeX
@article{Bui2024,
author = {Bui, Vivian N V and Daugaard, Tina F and Sorensen, Boe S and Nielsen, Anders L},
title = {Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2024.150395}
}
EUVIMED